Adhoc: Relief Therapeutics Holding SA: Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders 27-Dec-2022